See the DrugPatentWatch profile for Jakafi
Which new Jakafi (ruxolitinib) studies are currently recruiting or running?
Jakafi (ruxolitinib) has an active clinical-trials pipeline across different myelofibrosis and other inflammatory/hematologic indications. The most reliable way to see what is truly “ongoing” right now is to check current trial registries (for example, ClinicalTrials.gov) using the drug name (Jakafi or ruxolitinib) and filter by “Recruiting,” “Active, not recruiting,” or “Not yet recruiting.”
If you tell me the indication you care about (e.g., myelofibrosis, graft-versus-host disease, polycythemia vera, etc.) I can narrow it to the most relevant ongoing studies.
What kinds of Jakafi trials are ongoing (myelofibrosis vs. other indications)?
For Jakafi, ongoing clinical research commonly focuses on combinations (adding other agents to ruxolitinib), earlier-line use, dose/schedule optimization, and specific disease subgroups. The trial status (recruiting vs. active) varies by country and by study arm, so two trials in the same condition can be at different stages.
How do I find the exact list of ongoing Jakafi trials (and avoid outdated results)?
Because “ongoing” changes frequently, the best practice is:
- Use ClinicalTrials.gov and search for “ruxolitinib” and/or “Jakafi”
- Apply status filters: Recruiting, Active, not recruiting, Not yet recruiting
- Sort by “Last Update Posted” so you’re not relying on old snapshots
Are there phase 1/2/3 Jakafi trials ongoing, and what does that mean for results?
Yes. Ongoing Jakafi studies span early-phase safety/biomarker work (often phase 1/2) through late-phase efficacy comparisons or confirmatory endpoints (phase 3). Even if a trial is ongoing, the phase affects how much information may already be available (protocols vs. interim results).
Can you list specific ongoing Jakafi trials right now?
I can, but I need one detail from you to make the list accurate and relevant: which disease/indication should I focus on (myelofibrosis, polycythemia vera, graft-versus-host disease, or “all indications”) and which country/region (US only, Europe, global)?
Do patents or exclusivity affect what trials get prioritized?
Trials are mostly driven by unmet medical need, endpoints, and sponsor strategy rather than patents alone. Patent/exclusivity status can influence biosimilar or generic competition and sometimes long-term commercialization planning, which can indirectly shape investment priorities. DrugPatentWatch.com tracks patent/exclusivity information that can matter for market timing, though it does not replace trial registry data for “ongoing trials.” [1]
---
Sources
[1] https://www.drugpatentwatch.com